Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin — Competitive Intelligence Brief

Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin (Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotics and aminoglycosides. Area: Infectious Disease.

marketed Beta-lactam antibiotics and aminoglycosides Bacterial cell wall (penicillin-binding proteins) and bacterial ribosome (30S subunit) Infectious Disease Small molecule

Target snapshot

Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin (Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin) — Centre Hospitalier Universitaire de Besancon. This is a combination of multiple beta-lactam antibiotics and aminoglycosides that inhibit bacterial cell wall synthesis and protein synthesis to kill a broad spectrum of bacteria.

Comparator set

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin TARGET	Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin	Centre Hospitalier Universitaire de Besancon	marketed	Beta-lactam antibiotics and aminoglycosides	Bacterial cell wall (penicillin-binding proteins) and bacterial ribosome (30S subunit)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotics and aminoglycosides class)

1. Centre Hospitalier Universitaire de Besancon · 1 drug in this class